A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Phase 1 Completed 32 enrolled Jiangsu HengRui Medicine Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The study is being conducted to evaluate the tolerability, safety and efficacy of SHR-1210 in combination with Apatinib and Fluzoparib in subjects with recurrent and metastatic triple negative breast cancer

Timeline

Start: 2019-06-04
Primary completion: 2021-02-09
Completion: 2021-02-09

Publications

Zhang Q, Shao B, Tong Z, Ouyang Q, Wang Y, Xu G, Li S, Li H. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer. BMC Med. 2022 Oct 3;20(1):321. doi: 10.1186/s12916-022-02527-6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Camrelizumab	Monoclonal antibody	200 mg	Intravenous
Subject	Fluzoparib	Small molecule	100 mg	Oral
Subject	Rivoceranib	Small molecule	375 mg	Oral
Subject	Rivoceranib	Small molecule	500 mg	Oral

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Summary

Timeline

Publications

Drugs

Indications